Age

19–any

Sex

ALL

Healthy volunteers

Not accepted

Males or females ≥ 19 years of age at time of consent
≥4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (13, 14)
Clinically stable SLE
Corticosteroid use: ≥ 5mg/day of prednisolone equivalent
Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks
* Antimalarials (≤400 mg/day)
* Azathioprine (≤3 mg/kg/day)
* Mycophenolate mofetil (≤3 mg/day)
* Tacrolimus (≤5mg/day)
* Methotrexate (≤20mg/week)
* Cyclosphosphamide (≤1mg/BSA/month)
Must understand and voluntarily sign an informed consent form including writing consent for data protection

Pregnant or lactating females
Acute infection with T \>38°C at the time of vaccination
Previous anaphylactic response to vaccine components or to egg
History of Guillain-Barre syndrome or demyelinating syndromes
Any condition including laboratory abnormality which places the subject at unacceptable risk
Subjects who decline to participate

Immunogenicity, Reactogenicity of Shingrix in SLE